The lawsuit echoed some of the arguments raised by leading drug manufactures, including Bristol Myers Squibb, which challenged the Biden administration last week. The company earned $46.2 billion in revenue last year, including about $11 billion from the blood-thinner Eliquis, one of the drugs that could be targeted for Medicare negotiation.